OUR GOAL IS TO BE A LEADER IN THE DEVELOPEMENT OF TARGETED THERAPIES FOR PATIENTS WITH CANCER AND OTHER DISEASES OF HIGH UNMET NEED
TRACON Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, Our lead product candidate, envafolimab, is a PD-L1 antibody that is being developed for the treatment of sarcoma. Our other product candidates are TRC102, a small molecule that is in Phase 2 clinical development for the treatment of mesothelioma; TRC253, a small molecule inhibitor of wild type and mutated forms of the androgen receptor that has completed Phase 2 clinical development for prostate cancer, that is being developed through a collaboration with Janssen Pharmaceutica N.V.; TJ004309, a CD73 antibody that is in Phase 1 testing, that is being developed through a collaboration with I-Mab Biopharma; multiple bispecific antibody programs in preclinical development that are being developed through a collaboration with I-Mab Biopharma.
TRACON offers partners a novel solution for clinical development and commercialization of their products in the U.S. TRACON is a CRO-independent company which offers our partners improved quality, decreased timelines, greater development control and reduced cost. We have executed several deals already using this novel partnering approach and our partners include J&J, 3D Medicines, Alphamab Oncology and I-Mab. We have conducted 13 clinical trials using our CRO-independent platform, including at all Phases of development. Employing this capability we serve as a solution for developing and commercializing oncology products in the US. The key to our partnering model is the strong and lasting alignment we create through our deal designs. We strive to create alignment through cost share and risk share deals for development and profit sharing upon product approval by the FDA. In select instances TRACON will conduct the trial(s) as well as absorb all the clinical trial costs. We have the expertise to lead US. commercialization as well. Our preference is to work with first-in-class, best-in-class or fast-follower oncology and other physician specialist prescribed products. Our deal structures are customized to meet the needs of each corporate partner.